Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial

Bone Marrow Transplantation

Volumn 26, Issue 10, 2000, Pages 1057-1060

  Svahn, B M ^a   Bjurman, B ^a   Myrback K E ^b   Aschan, J ^a   Ringden O ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic stem cell transplantation; Home care; Infections; Myeloablative therapy; Pancytopenia

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; SANGSTAT; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CAREGIVER; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HOME CARE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; MALE; NEUTROPENIA; PANCYTOPENIA; PATIENT CARE; PATIENT SATISFACTION; PILOT STUDY; PRIORITY JOURNAL; RECIPIENT; SAFETY; SIBLING; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; TWINS;

EID: 0033677261     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702672     Document Type: Article

References (25)

1. Bone-marrow transplantation
2. Allogeneic bone marrow transplantation for haematological malignancies - Controversies and recent advances
3. What is in store after stem-cell transplantation?
4. Infection complicating bone marrow transplantation
5. Immunological recovery after bone marrow transplantation: Role of age, graft-versus-host disease, prednisolone treatment and infections
6. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection
7. Protective environment for marrow transplant recipients. A prospective study
8. Developing a home chemotherapy service
9. Outpatient high-dose chemotherapy with autologous stem cell rescue for hematologic and nonhematologic malignancies
10. Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease
11. Low incidence of acute graft-versus-host disease, using unrelated HLA-A, -B and -DR compatible donors and conditioning including anti-T-cell antibodies
12. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients
13. A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia
14. Busulphan bioavail-ability
15. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
16. Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation
17. Experience with a cooperative bone marrow transplant program in Stockholm
18. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia
19. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age
20. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation
21. Variables predicting deep fungal infections in bone marrow transplant recipients
22. Impact of air filtration on nosocomial Aspergillus infections: Unique risk of bone marrow transplant recipients
23. Pulmonary aspergillosis in patients with leukaemia
24. Prophylaxis of infections in patients with aplastic anemia receiving allogeneic marrow transplants
25. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia